Instrument Inactif

Communiqués DMK Pharmaceuticals Corporation

Actions

DMKPQ

US00547W3079

Produits pharmaceutiques

Communiqués

01/07/24	DMK Pharmaceuticals : Management Change/Compensation Form 8 K	PU
03/02/24	DMK Pharmaceuticals Commences Restructuring Proceeding	NE
21/12/23	DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI	AQ
28/11/23	DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update	AQ
14/11/23	DMK Pharmaceuticals: Q3 Earnings Snapshot	AQ
14/11/23	DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update	AQ
13/11/23	DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023	AQ
30/10/23	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
20/10/23	DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
19/10/23	DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth	AQ
10/10/23	DMK Pharmaceuticals : Failure to Satisfy Listing Rule - Form 8-K	PU
07/09/23	Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus	AQ
01/09/23	Adamis Pharmaceuticals : Shareholder Director Nominations - Form 8-K	PU
30/08/23	Adamis Pharmaceuticals : Material Agreement - Form 8-K	PU
21/08/23	Adamis: Q2 Earnings Snapshot	AQ
21/08/23	Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update	AQ
07/08/23	Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering	AQ
04/08/23	Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering	AQ
02/08/23	Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering	AQ
01/08/23	Adamis Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K	PU
31/07/23	Adamis Pharmaceuticals to Fund ZIMHI Clinical Study with University of Leiden Opioid Expert	AQ
28/07/23	Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert	AQ
26/06/23	Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder	AQ
22/06/23	Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention	AQ
16/06/23	ADAMIS PHARMACEUTICALS CORP Financial Statements and Exhibits (form 8-K/A)	AQ